Compare ASNS & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASNS | GRI |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.9M |
| IPO Year | 2022 | 2020 |
| Metric | ASNS | GRI |
|---|---|---|
| Price | $0.39 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | ★ 57.9M | 49.5K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,760,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $171.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.42 | N/A |
| 52 Week Low | $0.17 | $0.18 |
| 52 Week High | $3.63 | $11.12 |
| Indicator | ASNS | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 55.15 |
| Support Level | $0.38 | $2.18 |
| Resistance Level | $0.59 | $2.87 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 38.77 | 56.34 |
Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.